| 2026-08-11 | 10-Q | 10.5 | Lease Agreement dated May 8, 2026 by and between 184 Property Owner, LLC and Aquestive Therapeutics, Inc. |
|---|
| 2026-08-11 | 10-Q | 10.4 | Second Amendment to License Agreement, dated as of April 20, 2026, by and between Aquestive Therapeutics, Inc. and Atnahs Pharma UK Limited. |
|---|
| 2026-05-13 | 10-Q | 10.5 | Executive Employment Agreement dated as of March 16, 2026, by and between Aquestive Therapeutics, Inc. and Lori J. Braender. |
|---|
| 2026-05-13 | 10-Q | 10.4 | Termination of Executive Employment Agreement dated as of March 16, 2026, by and between Aquestive Therapeutics, Inc. and Lori J. Braender. |
|---|
| 2026-03-04 | 8-K | 10.3 | Share Purchase Commitment Agreement, by and between the Company and the parties thereto, dated March 3, 2026 |
|---|
| 2026-03-04 | 8-K | 10.2 | Warrant Issuance Agreement, by and between the Company and funds managed by RTW Investments, LP, dated March 3, 2026 |
|---|
| 2026-03-04 | 8-K | 10.1 | Amendment No. 1 to the Purchase and Sale Agreement, dated August 13, 2025, by and between the Company and funds managed by RTW Investments, LP, dated March 3, 2026 |
|---|
| 2025-11-05 | 10-Q | 10.1 | Purchase and Sale Agreement by and between Aquestive Therapeutics, Inc. and 4010 Royalty Investments ICAV, dated as of August 13, 2025** |
|---|
| 2025-05-12 | 10-Q | 10.1 | Consulting Agreement for Mark Schobel dated January 1, 2025. |
|---|
| 2024-03-05 | 10-K | 10.40 | Amendment to License and Supply Agreement between Aquestive and Atnahs Pharma UK Limited entered into March 27, 2023 (furnished herewith). |
|---|
| 2023-11-02 | 8-K | 10.3 | Form of Royalty Right Agreement** |
|---|
| 2023-11-02 | 8-K | 10.2 | Collateral Agreement dated as of November 1, 2023 among Aquestive Therapeutics, Inc., as Issuer, the other Grantors from time to time party thereto, U.S. Bank Trust Company, National Association, as Trustee, and U.S. Bank Trust Company, National Association, as Collateral Agent* |
|---|
| 2023-11-02 | 8-K | 10.1 | Form of Purchase Agreement |
|---|
| 2023-08-02 | 8-K | 10.1 | Inducement Offer to Exercise Common Stock Purchase Warrants Letter Agreement dated August 1, 2023 |
|---|
| 2023-03-31 | 10-K | 10.29 | License Agreement, dated as of October 26, 2022, by and between Aquestive Therapeutics, Inc. and Otter Pharmaceuticals, LLC (filed herewith) |
|---|
| 2023-03-31 | 10-K | 10.22 | Amendment No.1 to Purchase Agreement, dated as of August 6, 2021, by and between Aquestive Therapeutics, Inc. and the Purchasers signatory thereto (filed herewith). |
|---|
| 2023-03-31 | 10-K | 10.9 | Amendment No. 11 to Commercial Exploitation Agreement, dated as of August 15, 2008 (filed herewith). |
|---|
| 2022-11-01 | 10-Q | 10.1 | License and Supply Agreement, dated as of September 26, 2022, by and between Aquestive Therapeutics, Inc. and Atnahs Pharma UK Limited (filed herewith). |
|---|
| 2022-08-02 | 10-Q | 10.1 | Executive Employment Agreement between the Company and Daniel Barber, effective on July 15, 2022. |
|---|
| 2022-06-08 | 8-K | 10.1 | Form of Securities Purchase Agreement dated June 6, 2022, by and among Aquestive Therapeutics, Inc. and the purchasers |
|---|
| 2022-05-17 | 8-K | 10.1 | Separation Agreement, dated May 17, 2022, between Aquestive Therapeutics, Inc. and Keith J. Kendall. |
|---|
| 2022-05-17 | 8-K | 10.1 | Amendment No. 2 to the Purchase Agreement, dated as of May 13, 2022, by and among the Aquestive Therapeutics, Inc. and the Purchasers signatory thereto |
|---|
| 2022-05-04 | 10-Q | 10.1 | License, Development and Supply Agreement, dated as of March 2022, by and between Aquestive Therapeutics, Inc. and Haisco Pharmaceutical Group Co., Ltd. (filed herewith). |
|---|
| 2022-04-13 | 8-K | 10.2 | Registration Rights Agreement, dated as of April 12, 2022, by and between the Company and Lincoln Park. |
|---|
| 2022-04-13 | 8-K | 10.1 | Purchase Agreement, dated as of April 12, 2022, by and between the Company and Lincoln Park. |
|---|
| 2022-03-08 | 10-K | 10.26 | First Amendment to Executive Employment Agreement, dated as of June 30, 2021, by and between Aquestive Therapeutics, Inc. and Keith J. Kendall (filed herewith). |
|---|
| 2022-03-08 | 10-K | 10.25 | First Amendment to Executive Employment Agreement, dated as of June 30, 2021, by and between Aquestive Therapeutics, Inc. and Alexander Mark Schobel (filed herewith). |
|---|
| 2021-10-08 | 8-K | 10.1 | Consent Fee Letter, dated October 7, 2021, among Aquestive Therapeutics, Inc. and the Noteholder parties thereto |
|---|
| 2021-10-06 | 8-K | 10.1 | Waiver Agreement dated as of September 30, 2021, among Aquestive Therapeutics, Inc., at the Noteholder party thereto. |
|---|
| 2021-08-03 | 10-Q | 10.1 | Letter Agreement between the Company and A. Ernest Toth, Jr. , effective on June 15, 2021. |
|---|
| 2021-07-30 | 8-K | 10.1 | Third Amendment to License Agreement by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals Inc. (formerly, Cynapsus Therapeutics, Inc.) |
|---|
| 2021-03-26 | 8-K | 10.1 | Amendment No. 1 to the Equity Distribution Agreement, dated March 26, 2021, by and between Aquestive Therapeutics, Inc. and Piper Sandler & Co. |
|---|
| 2021-03-09 | 10-K | 10.23 | Purchase and Sale Agreement, dated as of November 3, 2020, by and between Aquestive Therapeutics, Inc. and MAM Pangolin Royalty, LLC (filed herewith). |
|---|
| 2021-03-09 | 10-K | 10.15 | Second Amendment to License Agreement, by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals, Inc., dated as of October 23, 2020 (filed herewith). |
|---|
| 2021-03-09 | 10-K | 10.8 | Separation Agreement, dated as of December 16, 2020, by and between Aquestive Therapeutics, Inc. and John T. Maxwell (filed herewith). |
|---|
| 2021-03-09 | 10-K | 10.3 | Form of 2020 Purchase Agreement in connection with the 2020 issuance of 12.5% Senior Secured Notes (filed herewith). |
|---|
| 2020-03-20 | 8-K | 10.1 | First Amendment to License Agreement, effective as of March 16, 2020, by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals Inc. (formerly, Cynapsus Therapeutics, Inc.) |
|---|
| 2020-03-11 | 10-K | 10.14 | Aquestive Therapeutics, Inc. Employee Stock Purchase Plan as Amended (filed herewith). |
|---|
| 2019-07-16 | 8-K | 10.2 | Collateral Agreement dated as of July 15, 2019 among Aquestive Therapeutics, Inc., as Issuer, the Other Grantors from time to time party thereto, U.S. Bank National Association, as Trustee, and U.S. Bank National Association, as Collateral Agent |
|---|
| 2019-07-16 | 8-K | 10.1 | Form of Purchase Agreement |
|---|
| 2019-06-18 | 8-K | 10.1 | Aquestive Therapeutics, Inc. Employee Stock Purchase Plan |
|---|
| 2018-11-06 | 10-Q | 10.4 | Employment Agreement dated September 10, 2018, by and between Aquestive Therapeutics, Inc., LLC and Lori J. Braender. |
|---|